Ananthsrinivas R. Chakilam

Ananthsrinivas R. Chakilam

Auto-generated profile, based on publicly available information

Ananthsrinivas R. Chakilam

Vertex Pharmaceuticals, Inc., 130 Waverly Street Cambridge, Massachusetts 02139

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2004 in Journal of Controlled Release
Verified
Journal Article
Closed access
ALAnatoly N. Lukyanov
Anatoly N. Lukyanov
Tamer ElbayoumiTamer Elbayoumi
Tamer Elbayoumi
ACAnanthsrinivas R. Chakilam
Ananthsrinivas R. Chakilam
VTVladimir P. Torchilin
Vladimir P. Torchilin

1 October 2007 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
HDHarikrishna Devalapally
Harikrishna Devalapally
ACAnanthsrinivas Chakilam
Ananthsrinivas Chakilam
Mansoor M. AmijiMansoor M. Amiji
Mansoor M. Amiji

1 January 2003 in Journal of Drug Targeting
Verified
Journal Article
Closed access
ZGZ. Gao
Z. Gao
ALA.N. Lukyanov
A.N. Lukyanov
ACA.R. Chakilam
A.R. Chakilam
VTV.P. Torchilin
V.P. Torchilin
Mixed micelles were prepared from poly(ethyleneglycol)-distearyl phosphoethanolamine (PEG2000-PE) and egg phosphatidylcholine. The micelles were covalently modified with the nucleosome-specific monoclonal antibody 2C5 known to recognize and bind a variety of tumor cells via their surface-bound nucleosomes. Covalent attachment of 2C5 antibody was performed via a micelle-incorporated PEG-PE with the distal terminus of the PEG block activated with p-nitrophenylcarbonyl group (pNP-PEG-PE). Micelle surface-attached 2C5 antibody maintained its specific activity. 2C5-targeted immunomicelles were able to carry more than 3 wt% of taxol. Taxol-loaded immunomicelles specifically recognized tumor cell lines of several types. The cytotoxicity of 2C5-targeted taxol-loaded immunomicelles in a cell culture model was much higher when compared with free taxol or taxol in non-targeted micelles.

19 February 2010 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
MTMitalee Tamhane
Mitalee Tamhane
ACAnanthsrinivas R. Chakilam
Ananthsrinivas R. Chakilam
AJAndrew Jayaraj
Andrew Jayaraj
VTVineet Thakkar
Vineet Thakkar
DTDavid R. Taft
David R. Taft
Context: VX-702 is a novel p38 mitogen-activated protein kinase inhibitor being developed to treat rheumatoid arthritis. Objective: To characterize the renal excretion profile of VX-702 using the isolated perfused rat kidney (IPRK) model. Methods: Studies were performed to assess the dose linearity of VX-702 excretion and to evaluate the effect of inhibitors of organic anion (probenecid) and organic cation (cimetidine) transport systems on VX-702 disposition. VX-702 excretion was studied over a range of doses targeting concentrations between 100 and 600 ng/mL. VX-702 (600 ng/mL) was also co-perfused with probenecid (1 mM) and cimetidine (2 mM). The results were compared to parallel experiments performed with methotrexate (MTX). Results: VX-702 excretion was linear over the range of doses studied, and clearance data were consistent with net reabsorption by the kidney. Transport inhibition studies indicate that VX-702 is not a substrate for renal organic anion and organic cation transport systems. MTX (500 ng/mL) also displayed net reabsorption in the IPRK, but secretory transport was inhibited upon co-administration with probenecid. This finding is consistent with previous IPRK studies that demonstrated inhibitory effects of NSAIDS on MTX excretion. Conclusion: Overall, this study suggests that a renal drug-drug interaction between VX-702 and MTX would be unlikely if these medications were co-administered.